Home  »  Finance   »  Honey At Amneal Pharmaceuticals Inc. (AMRX) Is Wor...

Honey At Amneal Pharmaceuticals Inc. (AMRX) Is Worth Your Money

Amneal Pharmaceuticals Inc. (NYSE:AMRX) price on Friday, May 27, fall -0.86% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $3.46.

A look at the stock’s price movement, the close in the last trading session was $3.49, moving within a range at $3.35 and $3.545. The beta value (5-Year monthly) was 1.25 while the PE ratio in trailing twelve months stood at 346.00. Turning to its 52-week performance, $6.21 and $3.08 were the 52-week high and 52-week low respectively. Overall, AMRX moved -12.41% over the past month.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Amneal Pharmaceuticals Inc.’s market cap currently stands at around $1.04 billion, with investors looking forward to this quarter’s earnings report slated for Feb 24, 2022 – Feb 28, 2022. Analysts project the company’s earnings per share (EPS) to be $0.19, which has seen fiscal year 2022 EPS growth forecast to increase to $0.81 and about $0.94 for fiscal year 2023. Per the data, EPS growth is expected to be -4.70% for 2022 and 16.00% for the next financial year.

Analysts have a consensus estimate of $535.93 million for the company’s revenue for the quarter, with a low and high estimate of $529 million and $548 million respectively. The average forecast suggests up to a 2.40% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2022 to grow to $2.17 billion, representing a 3.60% jump on that reported in the last financial year.

Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was 1 upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that AMRX is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.

AMRX’s current price about -1.56% and -10.90% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 44.62, while 7-day volatility ratio is 6.23% and 6.52% in the 30-day chart. Further, Amneal Pharmaceuticals Inc. (AMRX) has a beta value of 1.17, and an average true range (ATR) of 0.21.

In the market, a comparison of Amneal Pharmaceuticals Inc. (AMRX) and its peers suggest the former has performed considerably weaker. Data shows AMRX’s intraday price has changed -0.86% in last session and -38.87% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 2.47% and 1.76% respectively in the last trading.

If we refocus on Amneal Pharmaceuticals Inc. (NYSE:AMRX), historical trading data shows that trading volumes averaged 797.68K over the past 3 months. The company’s latest data on shares outstanding shows there are 149.89 million shares.

The 2.30% of Amneal Pharmaceuticals Inc.’s shares are in the hands of company insiders while institutional holders own 67.90% of the company’s shares. Current price change has pushed the stock -27.77% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the AMRX stock continues to rise going into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts